BNTC
Benitec Biopharma Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.36
+3.08%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$8.13
From 52W high−49.39%
Volume194117.00
Market cap$291.62M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$8.13
From 52W high
−49.39%
Volume
194117.00
Market cap
$291.62M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.2x
P/E (TTM)
—
RSI (14)
34.0
MomentumView details →
1D Return
+3.08%
YTD Return
−37.27%
SummaryUpdated Jun 1, 2026
Benitec Biopharma Inc. (NASDAQ:BNTC) is a development-stage biotechnology company founded in 1995 and headquartered in Hayward, California. The company went public in 2014 and focuses on developing novel genetic medicines using proprietary DNA-directed RNA interference (ddRNAi) technology. As a clinical-stage biotech firm, Benitec has built its pipeline around treating rare genetic diseases and chronic viral infections through innovative gene therapy approaches.
Similar companies
Latest newsMore news →
Benitec Biopharma received formal FDA feedback following a Type C meeting regarding an open-label, single-arm pivotal study for BB-301, with the FDA requesting additional available data including data from Benitec's OPMD Natural History Study.14d agoBenitec Biopharma Inc. changed its certifying accountant to Ernst & Young LLP on September 29, 2026.19d agoBenitec Biopharma Inc. dismissed Baker Tilly US, LLP as its independent auditor and appointed Ernst & Young LLP, effective September 18, 2026.25d ago